| HOME >> BIOLOGY >> TECHNOLOGY |
The results of the Phase III pivotal efficacy clinical trial in cancer patients with breakthrough pain announced earlier this year with BEMA Fentanyl are very encouraging.
"The results of our study demonstrated that fentanyl could be delivered rapidly, effectively and easily using the BEMA technology," said Finn. "Besides allowing greater absorption of fentanyl, the BEMA disc was easier to use, as it only required seconds to apply."
It is estimated that at least 60 percent of people with advanced cancer will experience significant pain of some type, oftentimes including breakthrough pain. For more information on BEMA Fentanyl, log on to http://www.bdsinternational.com/
SOURCE BioDelivery Sciences![]() Copyright©2007 PR Newswire. |